Peer-reviewed veterinary case report
Treatment of canine generalised demodicosis with amitraz plus virus
By Pekmezci, D et al.·Published in The Veterinary record·2014·Department of Internal Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of amitraz plus inactivated parapoxvirus ovis in the treatment of canine generalised demodicosis.
- Species:
- dog
Plain-English summary
A group of 16 dogs with generalized demodicosis, a skin condition caused by mites, were treated with either amitraz alone or amitraz combined with inactivated parapoxvirus ovis (iPPVO). The dogs treated with the combination therapy showed a quicker recovery, with clinical improvement noted in about 84.5 days compared to 104.3 days for those on amitraz alone. Both treatments were safe, with no side effects reported. This suggests that adding iPPVO to amitraz can help dogs recover faster from this challenging skin condition.
People also search for: dog skin mites treatment · generalized demodicosis in dogs · amitraz for dog skin problems
Abstract
Canine generalised demodicosis (CGD) is a challenging disease to treat effectively. Inactivated parapoxvirus ovis (iPPVO) could help to accelerate treatment with acaricidial therapy by altering the immune response. This study was designed to investigate the effects of treating CGD with amitraz plus iPPVO in terms of clinical outcomes and blood parameters. The study involved 16 dogs ranging in age from eight months to six years and weighing between 10 and 40 kg. Eight dogs were treated with amitraz and eight with amitraz plus iPPVO. Biochemical analysis of whole blood and serum, including serum C reactive protein (CRP) and serum amyloid A (SAA), was performed. Skin scrapings were conducted on days 0, 10, 40, 80 and 120 of treatment, and mite numbers were recorded. Clinical remission was determined according to mite numbers and clinical scores. The difference in mean whole remission days between the amitraz group (104.3 days) and the amitraz+iPPVO group (84.5 days) was statistically significant (P<0.05). Mean clinical scores were also significantly better in the amitraz+iPPVO (5.60) group when compared with the amitraz group (7.65). No adverse reactions were observed in either group. In view of these findings, the use of iPPVO in conjunction with amitraz can be recommended for treating CGD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24771532/